Physician profile
Mao Yang
NPI 1013556133
$3,916.90
in general payments reported to CMS, 2019-2025
15 companies · $678 in 2025
The $678 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.21 · 2021: $1,238 · 2022: $493 · 2023: $948 · 2024: $538 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Travel and Lodging: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.05 |
| Travel and Lodging | $199.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,409.39 | 2021-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $266.79 | 2021-2023 | Acuvue |
| Alcon Vision LLC | $238.82 | 2021-2025 | Precision7, Total30, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $203.66 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $169.84 | 2023 | |
| Bausch & Lomb Americas INC. | $146.01 | 2024 | Miebo, Zenlens |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $115.44 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $85.90 | 2021-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.24 | 2021 | |
| Notal Vision, INC. | $35.00 | 2025 | Foresee Home |
| Harrow Eye, LLC | $27.30 | 2025 | Vevye |
| Dompe US, INC. | $25.65 | 2022 | |
| Optos, INC. | $13.52 | 2022 | |
| Abbvie INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mao Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.